Cinacalcet in the treatment of persistent XXXX after kidney transplantation.

@entity1 @entity2741 @entity3528 @entity460 @entity1011 @entity3151 @entity2742
BACKGROUND: @entity3528 persists in 30 - 50% of @entity1 after a successful kidney transplant and it is the most frequent cause of @entity2741 after transplant, contributing to graft loss and mortality. Several medical therapies have been studied for the treatment of this condition without clear benefit. Recently, interest has grown in the use of cinacalcet in kidney transplant recipients. METHODS: We describe the efficacy of cinacalcet in 18 kidney transplant @entity1 with persistent @entity2742 and progressive @entity2741 treated for a period of 12-months. We analyzed serum @entity460 , @entity3151 and parathyroid hormone levels every 6 months, and cinacalcet was titrated if necessary. Statistical analysis was performed using ANOVA. RESULTS: With therapy, all @entity1 exhibited significant reduction in parathyroid hormone levels, from a mean value of 242.04    105.82 pg/ml to a mean value of 145.62    54.99 pg/ml (p < 0.001) 12 months later. In addition, serum @entity460 levels normalized during the study period, from 11.16 mg/d to 9.95 mg/dl (mean values) (p < 0.001). No significant change in serum @entity1011 was found in this group of @entity1 . Cinacalcet was well tolerated, with no side effects documented. CONCLUSION: This preliminary experience suggests that cinacalcet may be useful in the treatment of persistent @entity2742 after kidney transplant. In addition, cinacalcet controlled @entity2741 , which has well known adverse effects after transplant. This was accomplished with no evidence of declining kidney function or limiting side effects.
